Challenger Ltd. (CGF) Report Interpretation

Overview

This FY26 results review assesses Challenger’s earnings, capital settings and medium-term outlook. Goldman Sachs considers the medium-term framework broadly consistent with expectations and sees potential upside from capital management, while treating the softer FY27 outlook as partly distorted by identified one-off items.

Core views

Challenger’s FY26 normalized result was broadly in line with its guidance and with Goldman Sachs expectations. FY26 normalized NPAT was A$467.6m, the midpoint of the A$455-480m guidance range, while normalized basic EPS was 68.1cps, also at the midpoint of the 66-70cps range. For 2H26, normalized NPAT of A$238.7m exceeded Goldman Sachs’ A$237.8m estimate and company-compiled consensus of A$234.1m; normalized basic EPS of 34.8cps also slightly exceeded both. The statutory result was materially weaker, with 2H26 statutory NPAT of A$166.9m versus Goldman Sachs’ A$261.6m estimate, principally alongside weak investment experience. Medium-term guidance appears broadly aligned with expectations. Challenger targets after-tax operating ROE of 12-14%; its 2H26 group ROE was 11.7%, versus an approximately 11.2% target on the prior basis. The report sees roughly 1.3 percentage points of improvement at the midpoint as broadly consistent with expected ROE gains under new capital standards. The company also targets 8-10% operating EPS CAGR over three to five years. Goldman Sachs says this broadly matches consensus normalized EPS growth, but highlights uncertainty over the extent to which consensus incorporates buybacks and book growth funded by capital releases; meaningful buybacks could therefore create further upside. New APRA capital standards reshaped the capital and payout framework. Challenger reduced its capital target range to 1.15-1.35x from 1.3-1.7x, with the midpoint falling from 1.50x to 1.25x. Its pro forma capital position under the new standards was 1.50x at FY26, compared with 1.52x at 3Q26. Goldman Sachs expects the buyback and special dividend to leave capital slightly above the top of the new target range, where it believes the company would be comfortable operating. The company announced a further A$300m buyback in addition to the A$150m program already under way. It also reset the dividend payout target to 65-75% of core basic EPS from 30-50% of normalized basic EPS; the midpoint of the new range is equivalent to 46% of normalized basic EPS. FY26 and 2H26 normalized payout ratios were 46.3% and 46.0%, excluding the 1.5cps special dividend. FY27 guidance is softer than external forecasts but is not viewed as a major issue because disclosed one-offs explain much of the gap. Core basic EPS guidance of 45-49cps implies a midpoint about 6% above FY26, while reconciled normalized EPS guidance is 70.9cps versus Goldman Sachs’ 74.4cps forecast and consensus of 75.2cps. The report attributes 2.4cps of the variance to A$8m after-tax Calix Re costs and the Fidante/Channel Capital merger, which were not in Goldman Sachs’ numbers. On its calculations, the underlying drag is about 1.1cps, or 1.6% growth from FY26, reflecting tighter spreads and a shift toward investment-grade fixed income. It remains unclear whether FY27 guidance includes transition expenses after A$8.4m was incurred in FY26. Underlying operating indicators were mixed but generally supportive. The 2H26 COE margin was 3.17%, above Goldman Sachs’ 3.11% estimate and consensus of 3.09%, compared with 2.95% in 1H26 and 3.26% in 2H25. The sequential improvement reflected a 43bp rise in investment yield, partly offset by 15bp higher interest expense, 3bp higher distribution expenses and 3bp lower other income. The report notes that the increasing investment-grade allocation—from 76% to 80%—may create modest margin drag, even as fixed income represented 74% of assets and alternatives 14% at 4Q26. Investment experience was a major negative: 2H26 post-tax investment experience was -A$62.4m, versus Goldman Sachs’ A$23.9m estimate and consensus of A$2.4m. The Life business showed continued book growth, although mix and maturity are relevant. Total life book growth was 2.2% in 4Q26, comprising 1.6% annuity-book growth and 3.9% Index Plus growth. Retail sales rose 24.9% year on year, while institutional fixed-term sales fell 57.8%; longer-duration sales, including Lifetime and offshore reinsurance, rose 39.7%. FY26 offshore-reinsurance sales of A$1,235m exceeded the stated 50bn-yen annual target. FY26 maturity was 23%, meeting guidance, but FY27 maturity is guided to 26%. New-business tenor declined to 5.6 years in FY26 from 6.3 years in FY25 and 8.5 years in FY24. Life 2H26 EBIT of A$351.5m exceeded Goldman Sachs’ A$346.0m estimate, while Life ROE was 13.5% versus 13.9% in the prior corresponding period. Funds Management data improved on flows but were slightly softer on margin. Funds-management FUM reached A$108.7bn at 4Q26, above Goldman Sachs’ A$107.4bn estimate and A$104.5bn at 3Q26, supported by A$1.342bn of quarterly net inflows versus A$6.6bn of outflows in the prior corresponding period. Fidante generated A$0.4bn of net inflows and CIM A$0.9bn; market movements added about A$3.0bn and distributions subtracted about A$0.2bn. FUM-based income margin was 14.0bp, modestly below 14.4bp in 1H26 but above 13.8bp in 2H25. The Fidante and Channel Capital merger remains expected in late 1H27, subject to regulatory approvals and customary conditions, while CIM will remain wholly owned by Challenger. Goldman Sachs maintains its Buy rating and A$11.50 12-month target price. The target is weighted 85% to fundamental value and 15% to M&A value. The M&A value uses 15x P/E, broadly in line with peak multiples over the preceding five years. Fundamental value is weighted equally between DCF and an NTA multiple derived from a regression of FY28E sustainable ROTE against P/NTA across Goldman Sachs’ Financials coverage universe. The investment thesis rests on Challenger’s exposure to superannuation through Life and Funds Management, supportive yields for retail-annuity sales, diversified annuity distribution, and substantial excess capital.

Analysis framework

Goldman Sachs first compares FY26 earnings, margins, dividends and divisional performance with company guidance, its own forecasts and consensus. It then assesses the new medium-term ROE, EPS, capital and payout targets, adjusts its reading of FY27 guidance for disclosed one-off costs, and evaluates the operating drivers in Life and Funds Management. Its price target combines fundamental valuation with an M&A-value component.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Goldman Sachs assigns 50% of fundamental value to DCF, which estimates value from expected future cash flows discounted to today.

• Valuation methodsPB valuation

  Net tangible asset multiple derived from a regression of FY28E sustainable ROTE against P/NTA across the Financials coverage universe

  The other 50% of fundamental value uses a balance-sheet multiple linked to sustainable future returns on tangible equity.

• Other

  M&A value using a 15x P/E multiple

  Goldman Sachs gives M&A value a 15% weight in the target price and bases it on a P/E multiple described as broadly in line with peak multiples over the last five years.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Challenger Ltd. (CGF.AX)

  Primary covered company; Goldman Sachs sees medium-term targets as broadly achievable and excess capital as supportive of shareholder returns.

  Strengths

  Exposure to superannuation through Life and Funds Management, supportive retail-annuity sales conditions, diversified distribution, substantial excess capital and improving funds-management flows.

  Weaknesses

  FY27 normalized EPS guidance is below Goldman Sachs and consensus forecasts; funds-management income margin softened sequentially.

  Comparison

  2H26 normalized NPAT and EPS were slightly above Goldman Sachs estimates and consensus, while FY27 normalized EPS guidance of 70.9cps is below Goldman Sachs’ 74.4cps and consensus’ 75.2cps.

  Risks

  Margin- or ROE-dilutive growth, pricing competition from new entrants, and weak demand for annuity products.

Key data

• FY26 normalized NPATA$467.6mAt the midpoint of A$455-480m guidance.
• 2H26 normalized NPATA$238.7mVersus A$237.8m Goldman Sachs estimate and A$234.1m consensus.
• FY26 normalized basic EPS68.1cpsAt the midpoint of 66-70cps guidance.
• FY27 normalized EPS guidance70.9cpsVersus Goldman Sachs at 74.4cps and consensus at 75.2cps.
• Medium-term operating ROE target12-14%After-tax target; 2H26 group ROE was 11.7%.
• Medium-term operating EPS growth8-10% CAGRTarget over three to five years.
• Capital target range1.15-1.35xReduced from 1.3-1.7x under new APRA standards.
• Additional buybackA$300mOn top of the A$150m buyback already in progress.
• 4Q26 funds-management FUMA$108.7bnUp from A$104.5bn at 3Q26, supported by A$1.342bn of net inflows.

Impact & implications

The report sees the new capital regime as supporting a lower operating capital range, larger distributions and potential buyback-driven EPS upside. It considers FY27 guidance modestly below forecasts but partly explained by Calix Re and merger costs; underlying margin pressure from tighter spreads and more investment-grade assets remains a key offset.

Risks

• Growth in margin-dilutive or ROE-dilutive channels or products.
• Competitive pressure on pricing from new entrants benefiting from the capital standards.
• Weak demand for Challenger’s annuity products.

What to watch

• Whether buybacks and capital releases exceed what consensus currently assumes.
• The composition of FY27 transition expenses and the effect of Calix Re and the Fidante/Channel Capital merger on earnings.
• Margin effects from tighter spreads and the rising allocation to investment-grade fixed income.
• FY27 maturity guidance of 26% and the pace and mix of annuity-book growth.
• Completion of the Fidante and Channel Capital merger in late 1H27, subject to regulatory approvals and closing conditions.